Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 350


Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?

Wettstein MS, Naimark D, Hermanns T, Herrera-Caceres JO, Ahmad A, Jewett MAS, Kulkarni GS.

Cancer Med. 2020 Mar 12. doi: 10.1002/cam4.2980. [Epub ahead of print]


Predictive Value of In Vivo MR Spectroscopy With Semilocalization by Adiabatic Selective Refocusing in Differentiating Clear Cell Renal Cell Carcinoma From Other Subtypes.

Ali HA, Couch MJ, Menezes R, Evans AJ, Finelli A, Jewett MA, Jhaveri KS.

AJR Am J Roentgenol. 2020 Apr;214(4):817-824. doi: 10.2214/AJR.19.22023. Epub 2020 Feb 11.


Simultaneous Vs Sequential Retroperitoneal, Thoracic and Cervical Resection of Post Chemotherapy Residual Masses in Patients With Metastatic Nonseminomatous Germ Cell Tumors of the Testis.

Nason GJ, Donahoe L, de Perrot M, Aditya I, Jewett MAS, Bedard PL, Hansen AR, Chung P, Warde P, Anson-Cartwright L, Sweet J, O'Malley M, Atenafu EG, Hamilton RJ.

Urology. 2020 Jan 28. pii: S0090-4295(20)30082-0. doi: 10.1016/j.urology.2019.12.032. [Epub ahead of print]


Identification of tumor size as the only factor associated with non-diagnostic biopsies in patients with small renal masses.

Gillis CJ, Rendon R, MacDonald LP, Jewett MAS, French C, Ajzenberg H, Almatar A, Abdolell M, Organ M.

Can Urol Assoc J. 2019 Nov 29. doi: 10.5489/cuaj.6103. [Epub ahead of print]


Identification of Prognostic Biomarkers in the Urinary Peptidome of the Small Renal Mass.

Di Meo A, Batruch I, Brown MD, Yang C, Finelli A, Jewett MAS, Diamandis EP, Yousef GM.

Am J Pathol. 2019 Dec;189(12):2366-2376. doi: 10.1016/j.ajpath.2019.08.015.


Prognostic urinary miRNAs for the assessment of small renal masses.

Di Meo A, Brown MD, Finelli A, Jewett MAS, Diamandis EP, Yousef GM.

Clin Biochem. 2020 Jan;75:15-22. doi: 10.1016/j.clinbiochem.2019.10.002. Epub 2019 Oct 28.


Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.

Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG.

J Urol. 2020 Apr;203(4):684-689. doi: 10.1097/JU.0000000000000588. Epub 2019 Oct 9.


Development and acceptability testing of a patient decision aid for individuals with localized renal masses considering surgical removal with partial or radical nephrectomy.

McAlpine K, Breau RH, Stacey D, Knee C, Jewett MAS, Cagiannos I, Morash C, Lavallée LT.

Urol Oncol. 2019 Nov;37(11):811.e1-811.e7. doi: 10.1016/j.urolonc.2019.08.014. Epub 2019 Sep 17.


Searching for prognostic biomarkers for small renal masses in the urinary proteome.

Di Meo A, Batruch I, Brown MD, Yang C, Finelli A, Jewett MA, Diamandis EP, Yousef GM.

Int J Cancer. 2020 Apr 15;146(8):2315-2325. doi: 10.1002/ijc.32650. Epub 2019 Nov 6.


Application of Hereditary Renal Cell Carcinoma Risk Criteria to a Large Prospective Database.

Kushnir I, Kirk L, Mallick R, Kim RH, Graham GE, Breau RH, Lattouf JB, Violette PD, Pautler SE, Care M, Kapoor A, Jewett MAS, Wood L, Tanguay S, Heng DYC, Basappa NS, So A, Pouliot F, Reaume NM.

Clin Oncol (R Coll Radiol). 2020 Jan;32(1):e10-e15. doi: 10.1016/j.clon.2019.07.010. Epub 2019 Aug 1.


Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients.

Salama Y, Albanyan S, Szybowska M, Bullivant G, Gallinger B, Giles RH, Asa S, Badduke C, Chiorean A, Druker H, Ezzat S, Hannah-Shmouni F, Hernandez KG, Inglese C, Jani P, Kaur Y, Krema H, Krimus L, Laperriere N, Lichner Z, Mete O, Sit M, Zadeh G, Jewett MAS, Malkin D, Stockley T, Wasserman JD, Xu W, Schachter NF, Kim RH.

Clin Genet. 2019 Nov;96(5):461-467. doi: 10.1111/cge.13613. Epub 2019 Aug 6.


Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours.

Chung P, O'Malley ME, Jewett MAS, Bedard PL, Panzarella T, Sturgeon J, Moore MJ, Hamilton R, Hansen AR, Anson-Cartwright L, Gospodarowicz M, Warde P.

Eur Urol Oncol. 2019 Jul;2(4):437-442. doi: 10.1016/j.euo.2018.08.031. Epub 2018 Oct 2.


Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

De Bruijn RE, Mulders P, Jewett MA, Wagstaff J, Van Thienen JV, Blank CU, Van Velthoven R, Wood L, van Melick HE, Aarts MJ, Lattouf JB, Powles T, De Jong IJ, Rottey S, Tombal B, Marreaud S, Collette S, Collette L, Haanen JB, Bex A.

Eur Urol. 2019 Oct;76(4):437-440. doi: 10.1016/j.eururo.2019.06.006. Epub 2019 Jun 18.


Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG.

J Clin Oncol. 2019 Aug 10;37(23):2062-2071. doi: 10.1200/JCO.19.00107. Epub 2019 Jun 19.


Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma.

Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA.

Can Urol Assoc J. 2019 Jun;13(6):166-174. doi: 10.5489/cuaj.5786. No abstract available.


Optimal Management of High-risk Stage I Nonseminomatous Germ Cell Tumor: Surveillance is the Preferred Option.

Hamilton RJ, Jewett MAS, Warde P, Hansen A.

Eur Urol Focus. 2019 Sep;5(5):702-703. doi: 10.1016/j.euf.2019.05.003. Epub 2019 May 22.


Role of Active Surveillance for Localized Small Renal Masses.

Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M, Volpe A, Jewett MAS, Kutikov A, Pierorazio PM; Young Academic Urologists Kidney Cancer working group of the European Urological Association.

Eur Urol Oncol. 2018 Aug;1(3):177-187. doi: 10.1016/j.euo.2018.05.001. Epub 2018 May 26. Review.


Long-term oncological outcomes of patients with paratesticular sarcoma.

Goldberg H, Wong LM, Dickson B, Catton C, Yap SA, Alkasab T, Evans A, van der Kwast T, Jewett MAS, Hamilton RJ.

BJU Int. 2019 Nov;124(5):801-810. doi: 10.1111/bju.14775. Epub 2019 May 6.


Treatment of Relapse of Clinical Stage I Nonseminomatous Germ Cell Tumors on Surveillance.

Hamilton RJ, Nayan M, Anson-Cartwright L, Atenafu EG, Bedard PL, Hansen A, Chung P, Warde P, Sweet J, O'Malley M, Sturgeon J, Jewett MAS.

J Clin Oncol. 2019 Aug 1;37(22):1919-1926. doi: 10.1200/JCO.18.01250. Epub 2019 Feb 25.


Accuracy of renal tumour biopsy for the diagnosis and subtyping of papillary renal cell carcinoma: analysis of paired biopsy and nephrectomy specimens with focus on discordant cases.

Prendeville S, Richard PO, Jewett MAS, Kachura JR, Sweet JM, van der Kwast TH, Cheung CC, Finelli A, Evans AJ.

J Clin Pathol. 2019 May;72(5):363-367. doi: 10.1136/jclinpath-2018-205655. Epub 2019 Feb 12.


Applying Radiomics to Predict Pathology of Postchemotherapy Retroperitoneal Nodal Masses in Germ Cell Tumors.

Lewin J, Dufort P, Halankar J, O'Malley M, Jewett MAS, Hamilton RJ, Gupta A, Lorenzo A, Traubici J, Nayan M, Leão R, Warde P, Chung P, Anson Cartwright L, Sweet J, Hansen AR, Metser U, Bedard PL.

JCO Clin Cancer Inform. 2018 Dec;2:1-12. doi: 10.1200/CCI.18.00004.


Germ Cell Testicular Tumors-Contemporary Diagnosis, Staging and Management of Localized and Advanced disease.

Goldberg H, Klaassen Z, Chandrasekar T, Fleshner N, Hamilton RJ, Jewett MAS.

Urology. 2019 Mar;125:8-19. doi: 10.1016/j.urology.2018.12.025. Epub 2018 Dec 28. Review.


ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up.

Honecker F, Aparicio J, Berney D, Beyer J, Bokemeyer C, Cathomas R, Clarke N, Cohn-Cedermark G, Daugaard G, Dieckmann KP, Fizazi K, Fosså S, Germa-Lluch JR, Giannatempo P, Gietema JA, Gillessen S, Haugnes HS, Heidenreich A, Hemminki K, Huddart R, Jewett MAS, Joly F, Lauritsen J, Lorch A, Necchi A, Nicolai N, Oing C, Oldenburg J, Ondruš D, Papachristofilou A, Powles T, Sohaib A, Ståhl O, Tandstad T, Toner G, Horwich A.

Ann Oncol. 2018 Aug 1;29(8):1658-1686. doi: 10.1093/annonc/mdy217.


Classification tree for the prediction of malignant disease and the prediction of non-diagnostic biopsies in patients with small renal masses.

Organ M, MacDonald LP, Jewett MAS, Ajzenberg H, Almatar A, Abdolell M, Acker MR, Rendon R.

Can Urol Assoc J. 2019 Apr;13(4):115-119. doi: 10.5489/cuaj.5196. Epub 2018 Sep 27.


Renal tumor biopsy: indicators, technique, safety, accuracy results, and impact on treatment decision management.

Herrera-Caceres JO, Finelli A, Jewett MAS.

World J Urol. 2019 Mar;37(3):437-443. doi: 10.1007/s00345-018-2373-9. Epub 2018 Jul 18. Review.


Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer.

Fransen van de Putte EE, Otto W, Hartmann A, Bertz S, Mayr R, Bründl J, Breyer J, Manach Q, Compérat EM, Boormans JL, Bosschieter J, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Burger M, van der Kwast TH, van Rhijn BWG.

Urol Oncol. 2018 Aug;36(8):361.e7-361.e13. doi: 10.1016/j.urolonc.2018.05.007. Epub 2018 Jun 5.


Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials.

Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M.

Can Urol Assoc J. 2018 Jun;12(6):173-180. doi: 10.5489/cuaj.5187.


Uncoupling Diagnosis and Treatment of Incidentally Imaged Renal Masses.

Nayan M, Jewett MAS, Finelli A.

JAMA Intern Med. 2018 May 1;178(5):727-728. doi: 10.1001/jamainternmed.2018.1180. No abstract available.


Gene expression signatures prognostic for relapse in stage I testicular germ cell tumours.

Lewin J, Soltan Ghoraie L, Bedard PL, Hamilton RJ, Chung P, Moore M, Jewett MAS, Anson-Cartwright L, Virtanen C, Winegarden N, Tsao J, Warde P, Sweet J, Haibe-Kains B, Hansen AR.

BJU Int. 2018 Nov;122(5):814-822. doi: 10.1111/bju.14372. Epub 2018 May 31.


Roles for active surveillance in renal cancer.

Herrera-Caceres JO, Jewett MAS.

Curr Opin Urol. 2018 Jul;28(4):375-382. doi: 10.1097/MOU.0000000000000506. Review.


The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer.

van de Putte EEF, Bosschieter J, van der Kwast TH, Bertz S, Denzinger S, Manach Q, Compérat EM, Boormans JL, Jewett MAS, Stoehr R, van Leenders GJLH, Nieuwenhuijzen JA, Zlotta AR, Hendricksen K, Rouprêt M, Otto W, Burger M, Hartmann A, van Rhijn BWG.

BJU Int. 2018 Dec;122(6):978-985. doi: 10.1111/bju.14238. Epub 2018 Apr 27.


Identifying the use and barriers to the adoption of renal tumour biopsy in the management of small renal masses.

Richard PO, Martin L, Lavallée LT, Violette PD, Komisarenko M, Evans AJ, Jain K, Jewett MAS, Finelli A.

Can Urol Assoc J. 2018 Aug;12(8):260-266. doi: 10.5489/cuaj.5065. Epub 2018 Apr 6.


Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor.

Leão R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, Ahmad AE, Anson-Cartwright L, Chung P, Hansen A, Warde P, Castelo-Branco P, O'Malley M, Bedard PL, Looijenga LHJ, Hamilton RJ.

J Urol. 2018 Jul;200(1):126-135. doi: 10.1016/j.juro.2018.02.068. Epub 2018 Feb 21.


A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.

Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ.

Eur Urol Focus. 2018 Dec;4(6):995-1001. doi: 10.1016/j.euf.2018.01.015. Epub 2018 Feb 7.


Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2017 Oct;11(10):310-320. doi: 10.5489/cuaj.4769. No abstract available.


Recommendations for followup of stage I and II seminoma: The Princess Margaret Cancer Centre approach.

Lieng H, Warde P, Bedard P, Hamilton RJ, Hansen AR, Jewett MAS, O'malley M, Sweet J, Chung P.

Can Urol Assoc J. 2018 Feb;12(2):59-66. doi: 10.5489/cuaj.4531. Epub 2017 Dec 1. Review.


The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians.

Jones J, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa N, Basiuk J, Canil C, Al-Asaaed S, Heng D, Wood L, Stacey D, Kollmannsberger C, Jewett MAS.

Can Urol Assoc J. 2017 Dec;11(12):379-387. doi: 10.5489/cuaj.4590. Epub 2017 Nov 1.


Impact of Granulocyte-colony Stimulating Factor on Bleomycin-induced Pneumonitis in Chemotherapy-treated Germ Cell Tumors.

Kwan EM, Beck S, Amir E, Jewett MA, Sturgeon JF, Anson-Cartwright L, Chung PW, Warde PR, Moore MJ, Bedard PL, Tran B.

Clin Genitourin Cancer. 2017 Sep 4. pii: S1558-7673(17)30267-7. doi: 10.1016/j.clgc.2017.08.012. [Epub ahead of print]


Natural History of Complex Renal Cysts: Clinical Evidence Supporting Active Surveillance.

Chandrasekar T, Ahmad AE, Fadaak K, Jhaveri K, Bhatt JR, Jewett MAS, Finelli A.

J Urol. 2018 Mar;199(3):633-640. doi: 10.1016/j.juro.2017.09.078. Epub 2017 Sep 20.


Benchmarking quality for renal cancer surgery: Canadian Kidney Cancer information system (CKCis) perspective.

Lawson KA, Saarela O, Liu Z, Lavallée LT, Breau RH, Wood L, Jewett MAS, Kapoor A, Tanguay S, Moore RB, Rendon R, Pouliot F, Black PC, Kawakami J, Drachenberg D, Finelli A.

Can Urol Assoc J. 2017 Aug;11(8):232-237. doi: 10.5489/cuaj.4397.


Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC).

Lavallée LT, Fitzpatrick R, Wood LA, Basiuk J, Knee C, Cnossen S, Mallick R, Witiuk K, Vanhuyse M, Tanguay S, Finelli A, Jewett MAS, Basappa N, Lattouf JB, Gotto GT, Al-Asaaed S, Bjarnason GA, Moore R, North S, Canil C, Pouliot F, Soulières D, Castonguay V, Kassouf W, Cagiannos I, Morash C, Breau RH.

J Cancer Educ. 2019 Feb;34(1):14-18. doi: 10.1007/s13187-017-1259-7.


Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative.

Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A.

Can Urol Assoc J. 2017 Jun;11(6):182-187. doi: 10.5489/cuaj.4264.


Setting Research Priorities for Kidney Cancer.

Jones JM, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa NS, Basiuk J, Canil C, Al-Asaaed S, Heng DYC, Wood L, Stacey D, Kollmannsberger C, Jewett MAS.

Eur Urol. 2017 Dec;72(6):861-864. doi: 10.1016/j.eururo.2017.04.011. Epub 2017 May 8.


An Immune Atlas of Clear Cell Renal Cell Carcinoma.

Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B.

Cell. 2017 May 4;169(4):736-749.e18. doi: 10.1016/j.cell.2017.04.016.


Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Kulkarni GS, Hermanns T, Wei Y, Bhindi B, Satkunasivam R, Athanasopoulos P, Bostrom PJ, Kuk C, Li K, Templeton AJ, Sridhar SS, van der Kwast TH, Chung P, Bristow RG, Milosevic M, Warde P, Fleshner NE, Jewett MAS, Bashir S, Zlotta AR.

J Clin Oncol. 2017 Jul 10;35(20):2299-2305. doi: 10.1200/JCO.2016.69.2327. Epub 2017 Apr 14.


CUA guideline on the management of cystic renal lesions.

Richard PO, Violette PD, Jewett MA, Pouliot F, Leveridge M, So A, Whelan TF, Rendon R, Finelli A.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):E66-E73. doi: 10.5489/cuaj.4484. Epub 2017 Mar 16. No abstract available.


28-year late spermatic cord relapse of a testicular non-seminomatous germ cell tumour, managed robotically.

Hayes JR, Jewett MA, Hamilton RJ.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E257-E260. doi: 10.5489/cuaj.3492. Epub 2016 Jul 12.


Structured assessment and followup for patients with hereditary kidney tumour syndromes.

Lattouf JB, Pautler SE, Reaume MN, Kim RH, Care M, Green J, So A, Violette PD, Saliba I, Major P, Silver S, Leicht R, Basiuk J, Tanguay S, Jewett MA, Drachenberg D; Kidney Cancer Research Network of Canada.

Can Urol Assoc J. 2016 Jul-Aug;10(7-8):E214-E222. doi: 10.5489/cuaj.3798. Epub 2016 Jul 12. Erratum in: Can Urol Assoc J. 2017 Aug;11(8):E325.


Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline.

Finelli A, Ismaila N, Bro B, Durack J, Eggener S, Evans A, Gill I, Graham D, Huang W, Jewett MA, Latcha S, Lowrance W, Rosner M, Shayegan B, Thompson RH, Uzzo R, Russo P.

J Clin Oncol. 2017 Feb 20;35(6):668-680. doi: 10.1200/JCO.2016.69.9645. Epub 2017 Jan 17. Erratum in: J Clin Oncol. 2017 Apr 1;35(10):1141.


Supplemental Content

Loading ...
Support Center